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ABSTRACT 
Bisphosphonates (BP), drugs that inhibit bone resorption, are used to minimize bone loss in long-duration 
spaceflight, extended bed rest, and acute spinal cord injury; however, the long term impact of BP use on 
recovery of bone after disuse is not well understood. This experiment tests the hypothesis that the BP 
zoledronic acid (ZOL) administered 7 days before hindlimb unloading (HU) will protect against loss of 
bone mass during 28 days of HU by suppressing bone resorption activity while also diminishing the 
ability of cancellous bone formation rate (BFR) to recover following HU. Male Sprague Dawley rats (6 mo) 
were assigned to aging control (AC), HU, and HU+ZOL groups and subjected to 28 days of HU, then to 56 
days of weight-bearing recovery (REC). One group of rats was given 2 fluorescent labels 7 days apart to 
measure BFR in the final week of HU and the other group was given the same labels in the final week of 
REC. Histomorphometric analyses of the proximal tibia and distal femur showed lower osteoclast surface, 
a measure of bone resorption, 35 days after injection and 119 days after injection (-50% and -75%, 
respectively, compared to HU).  This verified that ZOL successfully suppressed bone resorption.  Dynamic 
histomorphometry revealed that cancellous BFR was lower in ZOL+HU versus AC both immediately after 
HU (-96.6%) and after the recovery period (-99.9%) (p<0.05). However, quantitative computed 
tomography measures of cancellous volumetric bone mineral density (CN-vBMD) at the proximal tibia 
revealed that CN-vBMD was higher in ZOL+HU versus AC and HU after 28 days of HU (+120.0% and 
+109.5%, respectively) and higher than AC after the 56 day recovery period (+125.5%) (p<0.05). These data 
indicate ZOL is a potent suppressor of bone formation as well as resorption. While ZOL effectively 
inhibited disuse-induced bone loss, the prolonged suppression of BFR by ZOL after administration may be 
detrimental in long-term recovery of bone after disuse. 
  
 
 
 
 
